A company developing male contraception technology.

Contraline

Contraline is a venture-backed, clinical-stage biotechnology company developing the first long-lasting, non-hormonal, and reversible male contraceptive. 

Virginia Catalyst

i.Lab at UVA

FundRx

Rhia Ventures

Shangbay Capital

MBX Capital

Metaplanet Holdings

Google Ventures

Graphene Ventures

Amboy Street Ventures

Smith Ventures

LAUNCH

The Syndicate.com

Founders Fund

Jaffray Woodriff

Jason Calacanis

Talent Resources Ventures

Join us in welcoming Robert S. Goldman to the Contraline team! 👏

We are so excited to share that Contraline's first in-human trial shows safety with 12-month efficacy signals of the ADAM™ male contraceptive!

Read more about it here:
https://lnkd.in/gZ8KhMhi

Contraceptives should fit seamlessly into our lives. Don't you think?

Last week, our CEO Kevin Eisenfrats  and CTO  Yelena Tropsha, PhD attended and presented at the 4th International Congress on Male Contraception (ICMC) at Rockefeller University in New York. The conference showcased that the field has advanced significantly with three novel male contraceptive methods now in the clinic. Contraline’s presentation discussed the journey of developing our vas-occlusive implant, ADAM, from concept to human trials.

We celebrate all of the researchers who attended ICMC and choose to work on male contraception every day; together, we are on the brink of a cultural shift in shared reproductive responsibility.

Did you catch our CEO, Kevin Eisenfrats, on the Medsider podcast today?

Kevin shared the story of founding Contraline and lessons learned along the way. Here are some of the topics that were discussed:

💡 The history of male contraception
📚 Transitioning from academia to entrepreneurship
 🏃 Setting the right milestones and executing quickly
💰  Grants vs. fundraising in the early days of the company
🚀  Getting a diverse set of investors around the table such as MBX Capital, Founders Fund, GV (Google Ventures), and Jason Calacanis
🌎  Creative ways of engaging your future customers and stakeholders

Thank you Scott Nelson for featuring Contraline on the pod! 

Blog:
https://lnkd.in/eMhN8rmk

Listen on Spotify:
https://lnkd.in/eejph4fE

This week our CEO Kevin Eisenfrats joined some of our investors, partners, friends and other healthcare industry leaders at Fortune Brainstorm Health.  It was exciting to see advancing male reproductive health as one of the hot topics on stage. As quoted in the Fortune article:

"Still, the $30 billion global fertility industry overwhelmingly caters to women, according to Grand View Research—just a small sliver is targeted toward men. That’s also reflected in the social understanding of infertility, which is commonly believed to be a women’s issue."

"We actually call the male partner the ‘silent partner,’” said Dr. Brian A. Levine, MD, MS, FACOG, founding partner and practice director at CCRM Fertility of New York. In a common scenario, he said, a woman having trouble conceiving would undergo a battery of tests, get a clear bill of health on all of them, and come to him puzzled—at which point he tells them to get their boyfriend or husband tested. “And the question is always, ‘why?’” he added. “What we have is an education problem here.”

Thank you Fortune Brainstorm team for a great couple days!




Ft: Alice Zheng, Pita Navarro, Helene Servillon 🇵🇭, Martin Sandgren, Ariel Kramer, Neel Shah, Khaled Kteily, Pamela Pure, Deena Shakir

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Jul 18, 2024 7:00 AM	0e96ade0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 18, 2024 10:14 PM	5bba2307
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Jul 18, 2024 7:00 AM	615b2042
news basic	general	Jul 18, 2024 7:00 AM	40ae75c5
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
purchaser profile	merger_acquisitions
customer profile	customers

CONT

COM:CONTRALINE

Contraline